The Company has appointed Dr Nicole Van Der Weerden as Chief Executive Officer effective today.
“Arovella is now a clinical stage company and I am proud to be leading it at this pivotal time as we deliver on our objectives. I have great confidence in our platform, our strategy and the team behind it, and I am excited about what we will achieve together. I sincerely thank the Board and the entire Arovella team for their support and commitment” said Dr. Van Der Weerden.
Arovella’s Chairman, Mr David Williams, said: “I have worked very closely with Nicole now for six months and I am very happy with her CEO skills, knowledge of the science, but most of all her willingness to work with me on Business Development and at the pace I like to work. I am very optimistic about what we can do together in the short term. Nicole is very impressive and also has an impressive team with her. The Board and I will provide her with any support she requires. I am very much looking forward to working together. The Board is particularly happy with the results of the last 6 months being the successful manufacture of product for dosing, the signing of 6 hospitals for our trial, the dosing of the first patient and the great animal data in tumours”
Dr. Van Der Weerden’s salary will be $401,700 plus superannuation and will be eligible for Short Term Incentive (STI) and Long Term Incentive (LTI) bonuses of up to 40% of the salary paid for each incentive. There are no other changes made to employment terms.
Biography – Dr Nicole Van Der Weerden
Dr Van Der Weerden is an experienced biotechnology executive who joined Arovella in 2023 as Chief Operating Officer. Prior to Arovella, she spent over 18 years at Hexima Ltd in a range of roles including COO, CEO and Non-executive director. There, she was responsible for advancing Hexima's lead drug candidate through preclinical and clinical development. Dr. Van Der Weerden has a PhD in Biochemistry and MBA from Melbourne Business School and is Graduate of the Australian Institute of Company Directors.